HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Effect of vasopressin on esophageal varices blood flow in patients with cirrhosis: comparisons with the effects on portal vein and superior mesenteric artery blood flow.

AbstractBACKGROUND/AIMS:
Vasopressin reduces portal pressure which may be due to decreased portal inflow. However, it remains unclear whether vasopressin is able to selectively reduce esophageal varices blood flow. The aim of this study was to address this question.
METHODS:
Fifteen patients with cirrhosis and esophageal varices were included in this prospective study. Portal vein and superior mesenteric artery flow velocity were measured with a percutaneous echo-Doppler. Esophageal varices flow velocity was measured using a transesophageal echo-Doppler technique. Mean arterial pressure and heart rate were also recorded. These measurements were performed at baseline condition and 15 min after observer blind drug administration. In this study, two groups, six patients receiving placebo and nine patients receiving 0.3 U/min of vasopressin, were randomized according to the coded number.
RESULTS:
Placebo administration had no effect on systemic and splanchnic circulation. In contrast, vasopressin administration increased mean arterial pressure (p < 0.05) associated with a bradycardia (p < 0.01). In splanchnic circulation, vasopressin decreased portal vein (-32 +/- 3%, p < 0.01), superior mesenteric artery (-30 +/- 2%, p < 0.01), and esophageal varices flow velocity (-48 +/- 5%, p < 0.01). When the magnitude of these reductions was compared, ANOVA showed a significant difference (p < 0.01). Furthermore, the reduction in esophageal varices flow velocity was significantly higher than that in portal vein flow velocity (p < 0.01) and that in superior mesenteric artery flow velocity (p < 0.01).
CONCLUSIONS:
These data support the view that vasopressin is able to selectively reduce esophageal varices blood flow. This effect, in addition to its well-established portal pressure reducing action, may play a role in its therapeutic efficacy in the treatment of variceal bleeding.
AuthorsT Iwao, A Toyonaga, K Oho, H Shigemori, T Sakai, C Tayama, H Masumoto, M Sato, K Tanikawa
JournalJournal of hepatology (J Hepatol) Vol. 25 Issue 4 Pg. 491-7 (Oct 1996) ISSN: 0168-8278 [Print] DENMARK
PMID8912148 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Vasoconstrictor Agents
  • Vasopressins
Topics
  • Aged
  • Blood Flow Velocity (drug effects)
  • Blood Pressure (drug effects)
  • Esophageal and Gastric Varices (complications, drug therapy, physiopathology)
  • Female
  • Heart Rate (drug effects)
  • Humans
  • Infusions, Intravenous
  • Liver Cirrhosis (complications, drug therapy, physiopathology)
  • Male
  • Mesenteric Artery, Superior (physiology, ultrasonography)
  • Middle Aged
  • Portal Vein (physiology, ultrasonography)
  • Prospective Studies
  • Ultrasonography, Doppler
  • Vasoconstrictor Agents (administration & dosage)
  • Vasopressins (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: